Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $667.13 | 9 | 50.2% |
| Debt forgiveness | $342.65 | 1 | 25.8% |
| Education | $319.97 | 4 | 24.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Olympus America Inc. | $565.07 | 3 | $0 (2022) |
| Astellas Pharma US Inc | $229.98 | 3 | $0 (2023) |
| Boston Scientific Corporation | $186.91 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $107.74 | 1 | $0 (2019) |
| PFIZER INC. | $89.99 | 1 | $0 (2018) |
| Coloplast Corp | $71.86 | 1 | $0 (2018) |
| Biohaven Pharmaceuticals, Inc. | $66.70 | 1 | $0 (2021) |
| TOLMAR Pharmaceuticals, Inc. | $11.50 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74.84 | 1 | Boston Scientific Corporation ($74.84) |
| 2023 | $74.99 | 1 | Astellas Pharma US Inc ($74.99) |
| 2022 | $106.66 | 1 | Olympus America Inc. ($106.66) |
| 2021 | $610.89 | 4 | Olympus America Inc. ($342.65) |
| 2020 | $127.26 | 2 | Olympus America Inc. ($115.76) |
| 2019 | $107.74 | 1 | Novartis Pharmaceuticals Corporation ($107.74) |
| 2018 | $172.37 | 3 | PFIZER INC. ($89.99) |
| 2017 | $55.00 | 1 | Astellas Pharma US Inc ($55.00) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/14/2024 | Boston Scientific Corporation | LithoVue (Device) | Food and Beverage | In-kind items and services | $74.84 | General |
| Category: LithoVue_URO | ||||||
| 02/01/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $74.99 | General |
| 03/09/2022 | Olympus America Inc. | iTIND System (Device) | Food and Beverage | In-kind items and services | $106.66 | General |
| Category: Urology Gynecology | ||||||
| 12/07/2021 | BOSTON SCIENTIFIC CORPORATION | LITHOVUE (Device) | Food and Beverage | Cash or cash equivalent | $101.55 | General |
| Category: LithoVue | ||||||
| 12/01/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 11/02/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $66.70 | General |
| Category: PRIMARY CARE | ||||||
| 03/31/2021 | Olympus America Inc. | — | Debt forgiveness | In-kind items and services | $342.65 | General |
| 11/12/2020 | TOLMAR Pharmaceuticals, Inc. | ELIGARD (Drug) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: Prostate Cancer | ||||||
| 10/13/2020 | Olympus America Inc. | UGN Laser Capital (Device) | Food and Beverage | In-kind items and services | $115.76 | General |
| Category: Urology/Gynecology | ||||||
| 05/29/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $107.74 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/12/2018 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $89.99 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2018 | Boston Scientific Corporation | FLEXIVA (Device) | Food and Beverage | In-kind items and services | $10.52 | General |
| Category: LITHOTRIPSY | ||||||
| 01/26/2018 | Coloplast Corp | TITAN (Device) | Food and Beverage | Cash or cash equivalent | $71.86 | General |
| Category: PENILE RECONSTRUCTION | ||||||
| 08/16/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $55.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 2,442 | 3,321 | $593,843 | $176,146 |
| 2022 | 34 | 2,527 | 3,931 | $761,418 | $184,672 |
| 2021 | 33 | 2,513 | 3,724 | $752,707 | $200,634 |
| 2020 | 37 | 3,301 | 4,830 | $1.1M | $235,411 |
All Medicare Procedures & Services
133 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 291 | 408 | $126,480 | $38,782 | 30.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 20 | 202 | $95,142 | $27,399 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 361 | 451 | $98,769 | $27,026 | 27.4% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 119 | 145 | $83,520 | $24,937 | 29.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 107 | 107 | $43,549 | $12,227 | 28.1% |
| 52356 | Crushing of stone of ureter with insertion of stent using an endoscope | Facility | 2023 | 18 | 21 | $21,441 | $6,962 | 32.5% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 324 | 375 | $17,250 | $6,758 | 39.2% |
| 52310 | Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | Office | 2023 | 19 | 21 | $16,191 | $5,257 | 32.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 50 | $16,100 | $5,039 | 31.3% |
| 55700 | Biopsy of prostate gland | Office | 2023 | 22 | 22 | $12,892 | $3,626 | 28.1% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2023 | 12 | 15 | $10,635 | $3,452 | 32.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 52 | $10,140 | $3,163 | 31.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $12,056 | $2,986 | 24.8% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 115 | 138 | $3,588 | $1,000 | 27.9% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 36 | $2,916 | $875.70 | 30.0% |
| 81003 | Automated urinalysis test | Office | 2023 | 299 | 365 | $2,190 | $801.21 | 36.6% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 55 | 82 | $1,804 | $679.78 | 37.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 54 | 60 | $2,040 | $650.18 | 31.9% |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | Office | 2023 | 137 | 298 | $2,086 | $640.27 | 30.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 64 | 81 | $648.00 | $631.55 | 97.5% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 22 | 31 | $1,860 | $597.68 | 32.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 21 | 22 | $3,014 | $548.45 | 18.2% |
| 76872 | Ultrasound scan of pelvic region through rectum | Office | 2023 | 22 | 22 | $1,738 | $532.56 | 30.6% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 51 | 73 | $1,241 | $462.82 | 37.3% |
| 51720 | Instillation of anti-cancer drug into bladder | Facility | 2023 | 12 | 22 | $4,686 | $390.28 | 8.3% |
About Dr. Rakesh Patel, M.D
Dr. Rakesh Patel, M.D is a Urology healthcare provider based in Lakeland, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962518837.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rakesh Patel, M.D has received a total of $1,330 in payments from pharmaceutical and medical device companies, with $74.84 received in 2024. These payments were reported across 14 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($667.13).
As a Medicare-enrolled provider, Patel has provided services to 10,783 Medicare beneficiaries, totaling 15,806 services with total Medicare billing of $796,862. Data is available for 4 years (2020–2023), covering 133 distinct procedure/service records.
Practice Information
- Specialty Urology
- Location Lakeland, FL
- Active Since 08/22/2006
- Last Updated 07/19/2022
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1962518837
Products in Payments
- UGN Laser Capital (Device) $115.76
- ENTRESTO (Drug) $107.74
- iTIND System (Device) $106.66
- LITHOVUE (Device) $101.55
- XTANDI (Drug) $89.99
- LithoVue (Device) $74.84
- TITAN (Device) $71.86
- NURTEC ODT (Drug) $66.70
- ELIGARD (Drug) $11.50
- FLEXIVA (Device) $10.52
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Lakeland
G Hodge, M.d, M.D
Urology — Payments: $33,885
Dr. Mark Swierzewski, M.d, M.D
Urology — Payments: $2,702
Mark Bandyk, Md, MD
Urology — Payments: $1,418
David Bowers, Md, MD
Urology — Payments: $699.53
Dr. Stanley Shrom, M.d, M.D
Urology — Payments: $510.88
Dr. Matthew Smith, M.d, M.D
Urology — Payments: $441.25